抄録
Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.
本文言語 | 英語 |
---|---|
ページ(範囲) | 299-308 |
ページ数 | 10 |
ジャーナル | Drug Delivery System |
巻 | 30 |
号 | 4 |
DOI | |
出版ステータス | 出版済み - 12月 25 2015 |
!!!All Science Journal Classification (ASJC) codes
- 薬科学